Boston Scientific is facing significant financial pressure ahead of its earnings report on April 22, 2026. The company is grappling with a class action lawsuit that alleges misleading statements about its U.S. electrophysiology growth, leading to analyst downgrades and declining investor confidence. Projected revenues of $5.19 billion and earnings of $0.80 per share signal potential growth, but Boston Scientific's challenges are compounded by increasing competition, regulatory hurdles regarding its $14.5 billion acquisition of Penumbra, and adverse trends in procedure volumes. As scrutiny intensifies, questions about the firm's ability to recover persist in the wake of earlier stock declines and ongoing litigation.
Click a month on the chart to update the report below.
